• 1. Excellent energy storage performance in NaNbO3-based relaxor antiferroeic ceramics under a low electric field
  XuxinCheng,XiaomingChen,PengyuanFan
• 2. Fe(iii)-mediated isomerization of α,α-diarylallylic alcohols to ketones via radical 1,2-aryl migration?
  Ziyang Deng,Changwei Chen,Sunliang Cui RSC Adv., 2016,6, 93753-93755
• 3. Evolution in surface coverage of CH3NH3PbI3?XClXvia heat assisted solvent vapour treatment and their effects on photovoltaic performance of devices
  Dhirendra K. Chaudhary,Pramendra Kumar,Lokendra Kumar RSC Adv., 2016,6, 94731-94738
• 4. Enabling stable MnO2 matrix for aqueous zinc-ion battery cathodes?
  Yiding Jiao,Liqun Kang,Jasper Berry-Gair,Kit McColl,Jianwei Li,Haobo Dong,Hao Jiang,Ryan Wang,Furio Corà,Dan J. L. Brett,Ivan P. Parkin J. Mater. Chem. A, 2020,8, 22075-22082
• 5. Enabling shape memory and healable effects in a conjugated polymer by incorporating siloxane via dynamic imine bond?
  Yaling Zhang,Chunhui Dai,Shiwei Zhou,Bin Liu Chem. Commun., 2018,54, 10092-10095

• Solvents and Organic Chemicals Organic Compounds Amines/Sulfonamides

Introduction to 3-(4-Methylpiperazin-1-yl)aniline and Its CAS No. 148546-99-0

3-(4-Methylpiperazin-1-yl)aniline, a compound with the chemical identifier CAS No. 148546-99-0, is a significant molecule in the field of pharmaceutical chemistry. This compound belongs to the class of piperazine derivatives, which are widely recognized for their diverse biological activities and potential applications in drug development. The structural features of 3-(4-Methylpiperazin-1-yl)aniline make it a valuable intermediate in the synthesis of various pharmacologically active agents.

The molecular structure of 3-(4-Methylpiperazin-1-yl)aniline consists of a benzene ring substituted with an aniline group at the 3-position and a piperazine ring at the 4-position, which is further substituted with a methyl group. This unique arrangement of functional groups contributes to its distinct chemical properties and biological interactions. The presence of both electron-donating and electron-withdrawing groups in its structure allows for a wide range of interactions with biological targets, making it a versatile scaffold for drug design.

In recent years, there has been growing interest in exploring the therapeutic potential of piperazine derivatives, including 3-(4-Methylpiperazin-1-yl)aniline. Research has demonstrated that this compound exhibits promising pharmacological effects, particularly in the context of central nervous system (CNS) disorders. Studies have shown that it can interact with various neurotransmitter receptors, such as serotonin and dopamine receptors, which are implicated in conditions like depression, anxiety, and neurodegenerative diseases.

One of the most notable applications of 3-(4-Methylpiperazin-1-yl)aniline is its role as a key intermediate in the synthesis of antipsychotic and antidepressant drugs. The piperazine moiety is known to enhance binding affinity to certain receptors, making it an effective component in developing medications that target these pathways. For instance, derivatives of this compound have been investigated for their potential to modulate dopamine D2 receptors, which are crucial in the treatment of schizophrenia and other psychotic disorders.

Moreover, the methyl group on the piperazine ring in 3-(4-Methylpiperazin-1-yl)aniline contributes to its metabolic stability and bioavailability. This feature is particularly important in drug development, as it ensures that the compound remains active in the body long enough to exert its therapeutic effects. Additionally, the aniline group provides a site for further functionalization, allowing chemists to tailor the molecule for specific pharmacological profiles.

Recent advancements in computational chemistry have also highlighted the importance of 3-(4-Methylpiperazin-1-yl)aniline in drug discovery. Molecular modeling studies have revealed that this compound can be effectively used to screen for new drug candidates by predicting its interactions with biological targets. These computational approaches have accelerated the process of identifying promising molecules for further experimental validation.

The synthesis of 3-(4-Methylpiperazin-1-yl)aniline involves multi-step organic reactions that require precise control over reaction conditions and reagent selection. The process typically begins with the formation of a Schiff base between aniline and formaldehyde, followed by cyclization to form the piperazine ring. Subsequent methylation and functional group modifications yield the final product. This synthetic route has been optimized to ensure high yield and purity, making it suitable for industrial-scale production.

In conclusion, 3-(4-Methylpiperazin-1-yl)aniline (CAS No. 148546-99-0) is a multifaceted compound with significant potential in pharmaceutical applications. Its unique structural features and biological activities make it a valuable tool for developing new drugs targeting CNS disorders. As research continues to uncover new therapeutic uses for piperazine derivatives, compounds like 3-(4-Methylpiperazin-1-yl)aniline are likely to play an increasingly important role in modern medicine.

• 1224684-96-1(N-methyl-4-(4-methylpiperazin-1-yl)aniline)
• 7479-12-1(4-[4-(4-aminophenyl)piperazin-1-yl]aniline)
• 21091-61-2(2-(4-phenylpiperazin-1-yl)ethan-1-amine)
• 314061-78-4(3-(4-ethylpiperazin-1-yl)aniline)
• 91703-23-0(N,N-dimethyl-4-(piperazin-1-yl)aniline)
• 57498-25-6(1-Ethyl-4-phenylpiperazine)
• 756751-92-5(Benzenamine,N-methyl-3-(1-piperazinyl)-)
• 1007210-84-5(N-methyl-3-(4-methyl-1-piperazinyl)-Benzenamine)
• 613-39-8(1,4-Diphenylpiperazine)
• 125422-03-9(3-(piperazin-1-yl)aniline)